Abstract

The present invention relates to the use of heterocyclic phosphonic compounds or compositions comprising the same for the treatment of fibrotic diseases. In particular, the present invention relates to compounds of general formula (1) as claimed herein or compositions comprising the same for use in the treatment of fibrotic diseases.

IPC Classes  ?

• A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

A field of peptides for their use as a medicament, in particular, for the prevention and the treatment of heart and blood vessel disease, more particularly, of heart and blood vessel diseases associated with vascular calcification is disclosed. A peptide according to the invention includes, or consists of, an amino acid sequence of at least 3 amino acids from the Calcium Binding Factor (CBF).

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to the use of heterocyclic phosphonic compounds or compositions comprising the same for the treatment of fibrotic diseases. In particular, the present invention relates to compounds of general formula (1) as claimed herein or compositions comprising the same for use in the treatment of fibrotic diseases.

IPC Classes  ?

• A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The present invention pertains to the field of peptides for their use as a medicament, in particular for the prevention and the treatment of heart and blood vessel disease, more particularly of heart and blood vessel diseases associated with vascular calcification. A peptide according to the invention comprises, or consists of, an amino acid sequence of at least 3 amino acids from the Calcium Binding Factor (CBF).

IPC Classes  ?

• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for controlling an apparatus for treating blood outside the human body, with a view to improving the operation of the apparatus, the apparatus including a semi-permeable membrane carrying out an exchange of solutes, referred to as dialysis, and of liquid, referred to as ultrafiltration, with the blood, the method including at least one iteration of the following steps: determination of a so-called instantaneous value, of an ultrafiltration coefficient corresponding to the ratio of an ultrafiltration flow rate to a difference in pressure, the so-called transmembrane pressure, on either side of the semi-permeable membrane, comparison of the instantaneous value with at least one previously determined characteristic value; and control of the treatment apparatus to reach a maximum value of the ultrafiltration coefficient, the control including a variation of the ultrafiltration flow rate up to a value corresponding to the maximum value of the ultrafiltration coefficient.

IPC Classes  ?

• B01D 61/32 - Controlling or regulating
• B01D 61/24 - Dialysis
• B01D 61/30 - AccessoriesAuxiliary operation
• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration

Abstract

The invention relates to a method for monitoring a filtration apparatus (20) with a view to improving the operation of said apparatus (20), said apparatus (20) comprising a semi-pervious membrane (22) that carries out filtration. Said method includes the following steps: determining a so-called instantaneous value of a filtration coefficient, said coefficient corresponding to the ratio of a filtration rate to a difference in so-called trans-membrane pressure between each side of said semi-pervious membrane (22); comparing said instantaneous value to at least one predetermined characteristic value; and controlling said treatment device (20) so as to reach a maximum value of said filtration coefficient. Said control includes a change in the filtration rate to a value corresponding to said maximum value of said filtration coefficient. Said maximum value of said coefficient can be determined by the method according to the invention.

IPC Classes  ?

• B01D 61/12 - Controlling or regulating
• B01D 61/22 - Controlling or regulating
• A23C 9/142 - Milk preparationsMilk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
• C12H 1/06 - Precipitation by physical means, e.g. by irradiation, vibrations

Abstract

The invention relates to a device for characterizing an extracorporeal blood treatment carried out by an extracorporeal treatment apparatus (704, 802) that expels an extracorporeal treatment liquid discharged through a discharge system (706). The device includes a sampling means (102, 104) for sampling, throughout the treatment, a filtrate amount at the outlet of the treatment apparatus (704, 802) and moreover includes a determining means (112, 116, 118, 120) for determining at least one parameter, related to said treatment, by means of analyzing at least one filtrate sample that is collected by the collecting means (102, 104). The device also includes a means (302, 304) for instantaneously sampling the used dialysate at a time t during the dialysis.

IPC Classes  ?

• A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes

Abstract

The invention relates to a method for controlling an apparatus (20) for treating blood outside the human body in order to improve the operation of said apparatus (20), said apparatus (20) including a semi-pervious membrane (22) for solute exchange, referred to as dialysis, and liquid exchange, referred to as ultrafiltration, with the blood, wherein said method includes the following steps: determining a so-called instantaneous value of an ultrafiltration coefficient, said coefficient corresponding to the ratio between an ultrafiltration flow and a so-called transmembrane pressure difference on either side of said semi-pervious membrane (22); comparing said instantaneous value with at least one previously determined characteristic value; and controlling the treatment apparatus (20) so as to reach a maximum value of said ultrafiltration coefficient, said control including a variation of the ultrafiltration flow up to a value corresponding to said maximum value of said ultrafiltration coefficient. The maximum value of said coefficient can be determined by the method of the invention.

IPC Classes  ?

• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61M 1/14 - Dialysis systemsArtificial kidneysBlood oxygenators

Abstract

The present invention relates to the use of heterocyclic phosphonic compounds or compositions comprising the same for the treatment of fibrotic diseases. In particular, the present invention relates to compounds of general formula (1) as claimed herein or compositions comprising the same for use in the treatment of fibrotic diseases.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like